Analysis of factors predicting mortality of new patients commencing renal replacement therapy 10 years of follow-up

BMC Nephrology

Volumn 15, Issue 1, 2014, Pages

  Browne, Oliver T ^a   Allgar, Victoria ^a   Bhandari, Sunil ^a,b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Calcium; Chronic kidney disease; Diabetes; Dialysis; eGFR; Mortality; Phosphate risk factors; Vascular

Indexed keywords

CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84892456085     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-15-20     Document Type: Article

References (51)

1. Chronic kidney disease management in the United Kingdom: NEOERICA project. Stevens PE, O'Donoghue DJ, de Lusignan S, Van Vlymen J, Klebe B, Middleton R, Hague N, New J, Farmer CK, Kidney Int 2007 72 92 99 10.1038/sj.ki.5002273 17440495 (Pubitemid 47014451)
2. UK Renal Registry 12th Annual Report (December 2009): chapter 4 UK ESRD prevalent rates in 2008: national and centre-specific analyses. Byrne C, Steenkamp R, Castledine C, Ansell D, Feehall J, Nephron Clin Pract 2010 115 Suppl 1 41 c67
3. Predictors of new-onset kidney disease in a community-based population. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D, JAMA 2004 291 844 850 10.1001/jama.291.7.844 14970063 (Pubitemid 38543772)
4. Cardiovascular risk factors in predialysis patients: baseline data from the Chronic Renal Impairment in Birmingham (CRIB) study. Wheeler DC, Townend JN, Landray MJ, Kidney Int 2003 63 201 203 10.1046/j.1523-1755.63.s84.45.x
5. Vitamin D levels and early mortality among incident hemodialysis patients. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadhani R, Kidney Int 2007 72 1004 1013 10.1038/sj.ki.5002451 17687259 (Pubitemid 47530570)
6. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Zoccali C, Mallamaci F, Tripepi G, Kidney Int 2003 63 105 110 10.1046/j.1523-1755.63.s85.25.x
7. The impact of population-based identification of chronic kidney disease using estimated glomerular filtration rate (eGFR) reporting. Richards N, Harris K, Whitfield M, O'Donoghue D, Lewis R, Mansell M, Thomas S, Townend J, Eames M, Marcelli D, Nephrol Dial Transplant 2008 23 556 561 18065790 (Pubitemid 351767654)
8. Vitamin D deficiency, self-reported physical activity and health-related quality of life: the Comprehensive Dialysis Study. Anand S, Kaysen GA, Chertow GM, Johansen KL, Grimes B, Dalrymple LS, Kurella Tamura M, Nephrol Dial Transplant 2011 Epub ahead of print
9. Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Mapes DL, Lopes AA, Satayathum S, Mccullough KP, Goodkin DA, Locatelli F, Fukuhara S, Young EW, Kurokawa K, Saito A, Bommer J, Wolfe RA, Held PJ, Port FK, Kidney Int 2003 64 339 349 10.1046/j.1523-1755.2003.00072.x 12787427 (Pubitemid 36714189)
10. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Matsushita K, van der Velde M, Astor BC, et al. Lancet 2010 375 9731 2073 2081 20483451
11. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Gansevoort RT, Matsushita K, van der Velde M, et al. Kidney Int 2011 80 1 93 104 10.1038/ki.2010.531 21289597
12. Analysis of risk factors for mortality of incident patients commencing dialysis in East Yorkshire, UK. Cherukuri A, Bhandari S, Q J Med 2010 103 41 48 10.1093/qjmed/hcp164
13. Early referral to the nephrologist and timely initiation of renal replacement therapy: a paradigm shift in the management of patients with chronic renal failure. Obrador GT, Pereira BJ, Am J Kidney Dis 1998 31 398 417 10.1053/ajkd.1998.v31.pm9506677 9506677 (Pubitemid 28124094)
14. Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent co morbidity-adjusted model. Messana JM, Chuang CC, Turenne M, Wheeler J, Turner J, Sleeman K, Tedeschi P, Hirth R, Am J Kidney Dis 2009 53 503 512 10.1053/j.ajkd.2008.10.047 19185402
15. A predictive model for progression of chronic kidney disease to kidney failure. Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, Levin A, Levey AS, JAMA 2011 305 15 1553 1559 10.1001/jama.2011.451 21482743
16. Dialysis discontinuation: quo vardis? Murtagh F, Cohen LM, Germain M, Adv Chronic Kidney Dis 2007 14 379 401 10.1053/j.ackd.2007.07.008 17904506 (Pubitemid 47451838)
17. Choosing not to dialyse: evaluation of planned non-dialytic management in a cohort of patients with end-stage renal failure. Smith C, Silva-Gane M, Chandra S, Warwicker P, Greenwood R, Farrington K, Nephron Clin Pract 2003 95 917 930
18. Diabetes mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES) 1999-2004. Whaley-Connell AT, Sowers JR, McFarlane SI, Norris KC, Chen SC, Li S, Qiu Y, Wang C, Stevens LA, Vassalotti JA, Collins AJ, Am J Kidney Dis 2008 51 Suppl 2 21 S29 18359404
19. Epigenetic mechanisms in diabetic vascular complications. Reddy MA, Natarajan R, Cardiovasc Res 2011 Epub ahead of print
20. Coronary flow reserve abnormalities in patientswith diabetes mellitus who have end-stage renal disease and normal epicardial coronary arteries. Ragosta M, Samady H, Isaacs RB, Gimple LW, Sarembock IJ, Powers ER, Am Heart J 2004 147 942 944 10.1016/j.ahj.2003.12.025 15199336 (Pubitemid 38880944)
21. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Schalkwijk CG, Stehouwer CD, Clin Sci (Lond) 2005 109 143 159 10.1042/CS20050025 16033329 (Pubitemid 41117297)
22. Effect of a multifactorial intervention on mortality in type 2 diabetes. Gæde P, Lund-Andersen H, Parving H-H, Pederse O, N Engl J Med 2008 358 580 589 10.1056/NEJMoa0706245 18256393 (Pubitemid 351214285)
23. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group, Lancet 1998 352 9131 837 853 9742976
24. Is there a need to optimize glycemic control in hemodialyzed diabetic patients? Feldt-Rasmussen B, Kidney Int 2006 70 1392 1394 10.1038/sj.ki.5001886 17024163 (Pubitemid 44527307)
25. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Cosio FG, Kudva Y, van der Velde M, Larson TS, Textor SC, Griffin MD, Stegall MD, Kidney Int 2005 67 2415 2421 10.1111/j.1523-1755.2005.00349.x 15882287 (Pubitemid 41623405)
26. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, Zagar T, Poole C, Lancet 2010 375 481 489 10.1016/S0140-6736(09) 61969-3 20110121
27. Effects of intensive glucose lowering in type 2 diabetes. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT, The ACCORD Study Group, N Engl J Med 2008 358 2545 2559 18539917 (Pubitemid 351831356)
28. 10-year follow-up of intensive glucose control in type 2 diabetes. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA, N Engl J Med 2008 359 1577 1589 10.1056/NEJMoa0806470 18784090
29. Cardiovascular disease in chronic renal insufficiency. Levin A, Foley RN, Am J Kidney Dis 2000 36 Suppl 3 24 S30
30. The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients. Tomiyama C, Higa A, Dalboni MA, Cendoroglo M, Draibe SA, Cuppari L, Carvalho AB, Neto EM, Canziani ME, Nephrol Dial Transplant 2006 21 2464 2471 10.1093/ndt/gfl291 16735378 (Pubitemid 44644518)
31. Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study. Foley RN, Wang C, Collins AJ, Mayo Clin Proc 2005 80 1270 1277 10.4065/80.10.1270 16212138 (Pubitemid 41395958)
32. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Heerspink HJ, Ninomiya T, Zoungas S, de Zeeuw D, Grobbee DE, Jardine MJ, Gallagher M, Roberts MA, Cass A, Neal B, Perkovic V, Lancet 2009 373 1009 1015 10.1016/S0140-6736(09)60212-9 19249092
33. Age, race, diabetes, blood pressure, and mortality among hemodialysis patients. Myers OB, Adams C, Rohrscheib MR, Servilla KS, Miskulin D, Bedrick EJ, Zager PG, J Am Soc Nephrol 2010 21 1970 1978 10.1681/ASN.2010010125 20947632
34. Blood pressure in chronic kidney disease stage 5D-report from a kidney disease: improving global outcomes controversies conference. Levin NW, Kotanko P, Eckardt KU, Kasiske BL, Chazot C, Cheung AK, Redon J, Wheeler DC, Zoccali C, London GM, Kidney Int 2010 77 273 284 10.1038/ki.2009.469 20016467
35. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F, AURORA Study Group, N Engl J Med 2009 360 1395 1407 10.1056/NEJMoa0810177 19332456
36. Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease. Navaneethan SD, Hegbrant J, Strippoli GF, Curr Opin Nephrol Hypertens 2011 20 146 152 10.1097/MNH.0b013e3283435f0e 21245764
37. Is lipid control necessary in hemodialysis patients? Cheung AK, Clin J Am Soc Nephrol 2009 Suppl 1 95 S101 doi: 102215/CJN.04780709
38. Pre- and postdialysis blood pressures are imprecise estimates of interdialytic ambulatory blood pressure. Agarwal R, Peixoto AJ, Santos SF, Zoccali C, Clin J Am Soc Nephrol 2006 1 389 398 10.2215/CJN.01891105 17699236
39. Blood pressure and mortality among hemodialysis patients. Agarwal R, Hypertension 2010 55 762 776 10.1161/HYPERTENSIONAHA.109.144899 20083728
40. Risk factors and metabolic mechanisms in the pathogenesis of uraemic cardiac disease. Bhandari S, Front Biosci 2011 16 1364 1387 10.2741/3794
41. Microalbuminuria as predictor of increased mortality in elderly people. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE, BMJ 1990 300 297 300 10.1136/bmj.300.6720.297 2106959 (Pubitemid 20047068)
42. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT, Chronic Kidney Disease Prognosis Consortium, Lancet 2010 375 2073 2081 20483451
43. GFR decline and mortality risk among patients with chronic kidney disease. Perkins RM, Bucaloiu ID, Kirchner H, Ashouian N, Hartle JE, Yahya T, J Am Soc Nephrol 2011 6 8 1879 1886 10.2215/CJN.00470111
44. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: longitudinal study. Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, Klag MJ, Powe N, Kidney Int 2006 70 351 357 10.1038/sj.ki.5001542 16738536 (Pubitemid 44086585)
45. Mortality predictors after 10 years of dialysis: a prospective study of Japanese hemodialysis patients. Ajiro J, Alchi B, Narita I, Omori K, Kondo D, Sakatsume M, Kazama JJ, Akazawa K, Gejyo F, Clin J Am Soc Nephrol 2007 2 653 660 10.2215/CJN.03160906 17699478
46. Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the calcification outcome in renal disease (CORD) study. Verbeke F, Van Biesen W, Honkanen E, Wikström B, Jensen PB, Krzesinski JM, Rasmussen M, Vanholder R, Rensma PL, CORD Study Investigators, Clin J Am Soc Nephrol 2010 6 153 159 20829424
47. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE, Atherosclerosis 2009 207 546 551 10.1016/j.atherosclerosis.2009.05. 013 19524924
48. Role of Klotho in aging, phosphate metabolism, and CKD. John GB, Cheng CY, Kuro-O M, Am J Kidney Dis 2011 Epub ahead of print
49. Klotho deficiency causes vascular calcification in chronic kidney disease. Hu MC, Shi M, Zhang J, Quiñones H, Griffith C, Kuro-o M, Moe OW, J Am Soc Nephrol 2011 22 124 136 10.1681/ASN.2009121311 21115613
50. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Komaba H, Goto S, Fujii H, Hamada Y, Kobayashi A, Shibuya K, Tominaga Y, Otsuki N, Nibu K, Nakagawa K, Tsugawa N, Okano T, Kitazawa R, Fukagawa M, Kita T, Kidney Int 2010 77 232 238 10.1038/ki.2009.414 19890272
51. Phosphate and Klotho. Kuro-o M, Kidney Int 2011 79 Suppl 121 20 S23